https://www.pharmanow.live/latest-news/zealand-pharma-opens-cambridge-research-hub-biologics-hybrid-modalities 2026-10-01T22:58:16+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Zealand Pharma Opens Cambridge Hub, Expands Biologics and Hybrid Modalities Zealand Pharma https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml-eu.globenewswire.com/Resource/Download/8e29e5a2-c1b8-45ea-89df-ae72dbee1c4a https://www.pharmanow.live/latest-news/ema-advances-new-pharmaceutical-legislation-implementation-antibiotic-vouchers-regulatory-sandbox 2026-10-01T22:58:54+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 EMA Advances New Pharmaceutical Legislation Implementation, Prioritising Antibiotic Vouchers and Regulatory Sandbox EMA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/05ae76ae-2499-4d51-bfbc-94d2a2451277/fe8a2186-bd3c-4adf-be0d-469294d4ebef.png https://www.pharmanow.live/latest-news/ema-type-ia-variation-deadline-november-2026 2026-10-01T22:59:28+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 EMA Sets 20 November 2026 Deadline for Type IA Variations to Secure Year-End Outcomes EMA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/05ae76ae-2499-4d51-bfbc-94d2a2451277/0957c3b0-65ed-42b8-bee0-177484afd1ce.png https://www.pharmanow.live/latest-news/regeneron-ubamatamab-73-percent-response-rate-lgsoc-phase-1-2-trial 2026-10-01T23:00:08+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Regeneron Achieves 73% Response Rate with Ubamatamab in Phase 1/2 LGSOC Trial Regeneron https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/05ae76ae-2499-4d51-bfbc-94d2a2451277/f6d30aac-cd4d-4ea0-9c5b-3e64b01e5546.png https://www.pharmanow.live/latest-news/achieve-life-sciences-appoints-benjamin-halladay-cfo-cytisinicline 2026-10-01T23:01:56+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Achieve Life Sciences Appoints Benjamin Halladay as CFO Ahead of Cytisinicline Commercialization Achieve Life Sciences https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/05ae76ae-2499-4d51-bfbc-94d2a2451277/965eab85-2a9a-4ee1-a375-cb2100d433e2.png https://www.pharmanow.live/latest-news/spyglass-pharma-acquires-avs-iol-manufacturing-phase-3 2026-10-01T23:01:12+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 SpyGlass Pharma Acquires AVS in $13M Deal to Secure IOL Manufacturing SpyGlass https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/05ae76ae-2499-4d51-bfbc-94d2a2451277/b699abcc-cd58-4ee4-903e-fe94d6a59161.png https://www.pharmanow.live/latest-news/60-degrees-pharmaceuticals-tafenoquine-babesiosis-interim-data-october-2026 2026-10-01T22:54:48+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 60 Degrees Pharmaceuticals Releases Tafenoquine Babesiosis Interim Data 60 Degrees https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/05ae76ae-2499-4d51-bfbc-94d2a2451277/c861da88-0906-4ca6-8cfa-b086cdbba103.png https://www.pharmanow.live/latest-news/regeneron-trevogrumab-courage-trial-muscle-preservation-glp1 2026-10-01T23:02:48+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Regeneron Achieves Phase 2 COURAGE Trial Milestone Confirming Trevogrumab Preserves Muscle Mass During GLP-1 Weight Loss Regeneron https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/05ae76ae-2499-4d51-bfbc-94d2a2451277/378dfeeb-f7d0-4cd9-88fb-966a08eabdc9.png https://www.pharmanow.live/latest-news/abbvie-upadacitinib-76-week-repigmentation-non-segmental-vitiligo 2026-10-01T23:03:40+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 AbbVie Achieves 76-Week Repigmentation Data for Upadacitinib in Non-Segmental Vitiligo AbbVie https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/05ae76ae-2499-4d51-bfbc-94d2a2451277/4b50a236-cb4f-46ff-a7d1-1400a01ed119.png https://www.pharmanow.live/latest-news/cardinal-health-cvs-health-distribution-agreement-extension-2032 2026-10-01T22:56:13+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Cardinal Health Signs CVS Health Distribution Extension Cardinal Health https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3134f357-6c59-458c-bf56-cbda2ea08f6f/2549c7d1-bc21-418d-9a65-9c8cba22638d.png https://www.pharmanow.live/latest-news/integrated-process-solutions-for-modern-manufacturing 2026-10-01T14:48:15+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Integrated Process Solutions for Modern Manufacturing Dec Group process solutions, pharmaceutical manufacturing automation, integrated process engineering, Frederic Dietrich Dec Group, powder handling to aseptic filling https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/Image(87)20261001144236.png https://www.pharmanow.live/latest-news/lilly-retatrutide-phase-3-weight-loss-diabetes-trial 2026-10-01T13:57:02+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Lilly Retatrutide Phase 3 Trial Yields 20.8% Diabetes Weight Loss Lilly Retatrutide https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/c34887b9-5401-4a7f-be50-65e326268175.png https://www.pharmanow.live/latest-news/roche-fda-priority-review-fenebrutinib-multiple-sclerosis 2026-10-01T13:57:03+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Roche Fenebrutinib Gets FDA Priority Review In Two MS Indications Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/a06341b4-1c75-4df3-a29c-74c1fffeb08c.png https://www.pharmanow.live/latest-news/acrotech-biopharma-launches-adquey-us-dermatology-fda-approval 2026-10-01T13:56:36+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Acrotech Launches Topical PDE4 Inhibitor ADQUEY In US Via FDA Nod Acrotech https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/d39d53cf-fef7-4b37-ac88-25394e273aee.png https://www.pharmanow.live/latest-news/shilpa-biologicals-launches-sb-himax-platform-biologics-development 2026-10-01T13:56:33+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Shilpa Biologicals Launches SB HiMax Biologics Speed Platform Shilpa Biologicals https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/18cff367-1437-45d2-b5a5-1fbeb063770b.png https://www.pharmanow.live/latest-news/lilly-zepbound-superior-weight-loss-wegovy-hd-72-week-analysis 2026-10-01T13:58:27+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Lilly Zepbound Beats Wegovy HD Weight Loss In 72-Week Trial Lilly Zepbound https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/91c419e3-2669-4143-ad9a-b456625c483f.png https://www.pharmanow.live/latest-news/sanofi-regeneron-expand-alliance-long-acting-immunology-antibodies 2026-10-01T13:56:36+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Sanofi And Regeneron Expand Immunology Alliance In $8B Grand Deal Sanofi https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/259ac5d0-2b53-4b76-a3fd-d3e7f4eef8ea.png https://www.pharmanow.live/latest-news/roche-giredestrant-evera-phase-iii-pfs-dual-pdufa-2026 2026-10-01T13:59:37+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Roche Phase III PFS Gains Hits Ahead Of Dual 2026 PDUFA Deadlines Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/ddac86bd-769e-43a7-b9da-895be0fa310c.png https://www.pharmanow.live/latest-news/regeneron-sanofi-alliance-expansion-long-acting-immunology-antibodies-2026 2026-10-01T14:03:50+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Regeneron & Sanofi Sign $8B Expansion For Four Long Antibodies Regeneron https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/277435a3-6cec-42be-8c7d-40ff0e1edefc.png https://www.pharmanow.live/latest-news/fda-domperidone-expanded-access-supply-closure-ind-importation 2026-10-01T14:06:22+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Ends Domperidone Access Supply; New IND Import Path Open FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/97d1b49c-b8ee-44f0-bd8b-aa38dce1461d.png https://www.pharmanow.live/latest-news/abbvie-zumilokibart-phase-2-atopic-dermatitis 2026-10-01T14:03:47+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Abbvie Zumilokibart Meets Easi 75; Key Cmc Qa Phase Three Roadmap AbbVie https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/c8759238-082b-40ff-92a5-7b6f3dbbccb7.png https://www.pharmanow.live/latest-news/zealand-pharma-survodutide-phase-iii-synchronize-2-weight-loss-type-2-diabetes 2026-10-01T14:10:40+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Zealand Survodutide Gains 13.1% Weight Loss In Phase 3 Trial Zealand Survodutide https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/e2052693-d301-4309-822d-7a1f9d1803dd.png https://www.pharmanow.live/latest-news/boehringer-ingelheim-survodutide-phase-iii-synchronize-2-weight-loss-results 2026-10-01T13:57:03+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Boehringer Survodutide Shows 13.1% Weight Loss In Phase III Trial Boehringer Survodutide https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml-eu.globenewswire.com/Resource/Download/d5e21fe1-beec-4d8a-8d99-4b080026b68f https://www.pharmanow.live/latest-news/fda-refreshes-drug-interaction-guidance-index-m12-october-2024-labeling 2026-10-01T14:10:39+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Refreshes M12 Drug Interaction And Oct Labeling Index FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/69cd8e88-0157-4306-b299-79603844e459.png https://www.pharmanow.live/latest-news/fda-biopharmaceutical-manufacturing-fellowship-curia-global-office-pharmaceutical-quality 2026-10-01T14:12:44+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Biotech Fellowship Places Fellows At Curia And OPQ Office FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/943ce243-1402-49cc-8fca-cff11e10e276/cb45aa56-b9ff-4dbf-ba00-08018c2b8f93.png https://www.pharmanow.live/latest-news/fda-cder-guidance-taxonomy-cmc-cgmp-ich-quality-categories 2026-10-01T19:04:43+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Publishes Updated CDER Guidance On CMC, CGMP, And ICH FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-cder-guidance-taxonomy-cmc-cgmp-ich-quality-categories20261001183921.webp https://www.pharmanow.live/latest-news/bristol-myers-squibb-fda-approval-camzyos-pediatric-ohcm 2026-10-01T10:44:01+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Bristol Myers Squibb Camzyos Wins Fda Approval For Pediatric Ohcm Bristol Myers https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3016413e-ac85-4c3f-ab8e-c1ca445a4a3a/f5d2e618-9277-4403-937c-b196cc5287a6.png https://www.pharmanow.live/latest-news/fda-updates-biological-product-deviation-codes-cber-reporting 2026-10-01T10:44:12+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Updates Biological Product Deviation Codes For Cber Reporting FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3016413e-ac85-4c3f-ab8e-c1ca445a4a3a/c2f1eb47-36b2-4595-9c8b-07cf876ac4ae.png https://www.pharmanow.live/latest-news/tapi-appoints-serge-rogasik-ceo-cdmo-growth-supply-chain 2026-10-01T10:44:03+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 Tapi Appoints Serge Rogasik As Ceo To Drive Cdmo Growth Expansion Tapi https://pharmanow.nyc3.cdn.digitaloceanspaces.com/https://ml-eu.globenewswire.com/Resource/Download/fd3f1b14-47a6-4f7f-bdb2-f93e7c6727b2 https://www.pharmanow.live/latest-news/fda-updates-biosimilars-action-plan-bsufa-iii 2026-10-01T10:49:37+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Updates Biosimilars Action Plan To Align With Bsufa Iii Goals FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/3016413e-ac85-4c3f-ab8e-c1ca445a4a3a/b71cb7c1-60d4-4a01-82ec-79d8bbfc0d7d.png https://www.pharmanow.live/latest-news/fda-e2br3-icsr-submission-toolkit-xml-schema-aems-regional-guide 2026-10-01T18:33:13+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Consolidates E2b Icsr Submission Toolkit With Regional Guides FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-e2br3-icsr-submission-toolkit-xml-schema-aems-regional-guide20261001183306.webp https://www.pharmanow.live/latest-news/fda-aems-e2br3-e2d-r1-icsr-submission-standards-2026 2026-10-01T18:29:53+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Aems Accepts E2b(R3) Updates Aligned With Ich E2d Standards FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-aems-e2br3-e2d-r1-icsr-submission-standards-202620261001182900.webp https://www.pharmanow.live/latest-news/fda-aems-e2b-r3-icsr-mandate-october-2026 2026-10-01T18:26:02+05:30 Pharma Now en 2026-10-01T00:00:00+05:30 FDA Mandates E2b Standard For All Icsr Submissions Via Aems Today FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-aems-e2b-r3-icsr-mandate-october-202620261001182454.webp https://www.pharmanow.live/latest-news/ema-womens-health-regulatory-roadmap-q4-2026 2026-10-01T15:15:35+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 EMA Sets Deadline for Women's Health Regulatory Roadmap After Amsterdam Workshop EMA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/ema-womens-health-regulatory-roadmap-q4-202620261001151524.webp https://www.pharmanow.live/latest-news/abbvie-abbv-295-phase-1-amylin-analog-monthly-dosing-easd-2026 2026-10-01T15:12:35+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 AbbVie Achieves Phase 1 Milestone for ABBV-295 Amylin Analog Supporting Monthly Dosing Intervals AbbVie https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-abbv-295-phase-1-amylin-analog-easd-202620261001151229.webp https://www.pharmanow.live/latest-news/roche-fda-priority-review-fenebrutinib-rms-ppms 2026-09-30T13:41:56+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 Roche's Fenebrutinib Gets FDA Priority Review For RMS And PPMS Roche https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/agents-data/images/news/5484c9ba-4f73-43ef-9a58-42efd650ec5a/19a67fd0-3ce6-4f3c-81a1-027aac7fc76a.png https://www.pharmanow.live/latest-news/abbvie-zumilokibart-phase-2-apex-part-b-atopic-dermatitis-phase-3 2026-10-01T15:11:35+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 AbbVie's Zumilokibart Hits Phase 2 Endpoint For Atopic Dermatitis AbbVie https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/abbvie-zumilokibart-phase-2-apex-part-b-atopic-dermatitis-phase-320261001151123.webp https://www.pharmanow.live/latest-news/astrazeneca-secures-stake-summit-therapeutics-2-billion-ivonescimab-deal 2026-10-01T15:11:02+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 AstraZeneca Secures 12% Stake In Summit For $2B Ivonescimab Asset AstraZeneca https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/astrazeneca-summit-therapeutics-2-billion-ivonescimab-deal20261001150702.webp https://www.pharmanow.live/latest-news/lilly-foundayo-outperforms-oral-semaglutide-weight-loss-indirect-achieve-3-analysis 2026-10-01T15:02:33+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 Lilly Foundayo Outperforms Oral Semaglutide In Weight Loss Trials Lilly https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/lilly-foundayo-oral-semaglutide-weight-loss-achieve-3-analysis20261001150221.webp https://www.pharmanow.live/latest-news/novo-nordisk-hengrui-oral-glp-1-deal-2-6-billion 2026-10-01T14:55:03+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 Novo Nordisk Signs $2.6 Billion Deal with Hengrui for Oral GLP-1 Candidate Novo Nordisk https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/novo-nordisk-hengrui-oral-glp-1-deal-2-6-billion20261001145357.webp https://www.pharmanow.live/latest-news/fda-crcg-lai-generics-workshop-december-2026-anda-submission 2026-10-01T13:41:56+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 FDA & CRCG Host December 2026 LAI Generics Workshop On ANDA Gaps FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-crcg-lai-generics-workshop-december-2026-anda-submission20261001134142.webp https://www.pharmanow.live/latest-news/fda-charges-indian-nationals-counterfeit-ozempic-distribution-scheme 2026-10-01T13:36:43+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 FDA Charges Two Indian Nationals In Fake Ozempic Ring FDA https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/fda-charges-indian-nationals-counterfeit-ozempic-distribution-scheme20261001133630.webp https://www.pharmanow.live/latest-news/telix-fda-fast-track-bipass-pre-biopsy-prostate-cancer-pet 2026-10-01T13:34:32+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 Telix Secures FDA Fast Track For BiPASS Prostate Cancer Program Telix https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/telix-fda-fast-track-bipass-pre-biopsy-prostate-cancer-pet20261001133429.webp https://www.pharmanow.live/latest-news/zealand-pharma-zupreme-1-phase-2-petrelintide-weight-loss-results 2026-10-01T13:34:09+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 Zealand Petrelintide Hits Double Digit Weight Loss In Phase Two Zealand Pharma https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/zealand-pharma-zupreme-1-phase-2-petrelintide-weight-loss-results20261001133040.webp https://www.pharmanow.live/latest-news/maat-pharma-chmp-rejection-xervyteg-fda-pre-ind-maat034-2026 2026-10-01T13:29:51+05:30 Pharma Now en 2026-09-30T00:00:00+05:30 MaaT Pharma Shifts MaaT034 To FDA Path After Xervyteg EU Rejection Maat Pharma https://pharmanow.nyc3.cdn.digitaloceanspaces.com/p/uploads/news/original/maat-pharma-chmp-rejection-xervyteg-fda-pre-ind-maat034-202620261001132425.webp